Last reviewed · How we verify
Positive Control
Positive control drug used to validate the efficacy of other treatments.
Positive control drug used to validate the efficacy of other treatments. Used for Metastatic non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | Positive Control |
|---|---|
| Also known as | Shingrix®, medication |
| Sponsor | UNION therapeutics |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
As a positive control, it serves as a reference point to ensure the effectiveness of other drugs in clinical trials. Its mechanism is well-established and widely recognized in the medical community.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
Common side effects
- Unknown
Key clinical trials
- The Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea
- Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer (NA)
- Effects of Positive Psychological Group Psychotherapy and Auricular Acupressure on Withdrawal Symptoms (NA)
- USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias (NA)
- Palestinian ParentText for Crisis (NA)
- Leveraging Community-clinical Linkages to Address Unmet Social Needs for People With Diabetes (NA)
- Procedural Framing and Epidural Steroid Injection Outcomes (NA)
- Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Positive Control CI brief — competitive landscape report
- Positive Control updates RSS · CI watch RSS
- UNION therapeutics portfolio CI